Given the rapidly evolving landscape of Artificial Intelligence, one of the biggest hurdles tech leaders often come across is ...

Boston and London biotech company Vertex Pharmaceuticals is on a roll. In the past year and a half, Vertex worked with CRISPR Therapeutics to develop the first CRISPR treatment approved by the U.S.

A new way to escalate privileges inside Google’s Vertex AI highlights a broader problem: Enterprises have a level of trust in ...

Vertex Pharmaceuticals (VRTX +0.28%) has long been known as the company to turn to for life-saving cystic fibrosis (CF) drugs, and this platform has helped it generate billions of dollars in earnings.

Vertex Pharmaceuticals stock was heading for a double-digit gain this year until recent weeks. The company is approaching an important turning point -- one that could set the tone for revenue growth.